PT - JOURNAL ARTICLE AU - Bae, Sua AU - Liu, Keyu AU - Pouliopoulos, Antonios N. AU - Ji, Robin AU - Jiménez-Gambín, Sergio AU - Yousefian, Omid AU - Kline-Schoder, Alina R. AU - Batts, Alec J. AU - Kokossis, Danae AU - Mintz, Akiva AU - Honig, Lawrence S. AU - Konofagou, Elisa E. TI - Transcranial Blood–Brain Barrier Opening in Alzheimer’s Disease Patients Using A Portable Focused Ultrasound System with Real-Time 2-D Cavitation Mapping AID - 10.1101/2023.12.21.23300222 DP - 2024 Jan 01 TA - medRxiv PG - 2023.12.21.23300222 4099 - http://medrxiv.org/content/early/2024/02/21/2023.12.21.23300222.short 4100 - http://medrxiv.org/content/early/2024/02/21/2023.12.21.23300222.full AB - Background Focused ultrasound (FUS) in combination with microbubbles has recently shown great promise in facilitating blood-brain barrier (BBB) opening for drug delivery and immunotherapy in Alzheimer’s disease (AD). However, it is currently limited to systems integrated within the MRI suites or requiring post-surgical implants, thus restricting its widespread clinical adoption. In this pilot study, we investigate the clinical safety and feasibility of a portable, non-invasive neuronavigated FUS system with integrated real-time 2D microbubble cavitation mapping.Methods A phase 1 clinical study with mild to moderate AD patients (N=6) underwent a single session of microbubble-mediated FUS to induce transient BBB opening (BBBO). Microbubble activity under FUS was monitored with real-time 2-D cavitation maps and dosing to ensure the efficacy and safety of the FUS treatment. Post-operative MRI was used for BBB opening and closure confirmation as well as safety assessment. Changes in AD biomarker levels in both blood serum and extracellular vesicles (EVs) were evaluated, while changes in amyloid-beta (Aβ) load in the brain were assessed through 18F-Florbetapir PET.Results BBBO was achieved in 5 out of 6 subjects with an average volume of 983±626 mm3 following FUS at the right frontal lobe both in white and gray matter regions. The outpatient treatment was completed within 34.8±10.7 min. Cavitation dose significantly correlated with the BBBO volume (R2>0.9, N=4), demonstrating the portable FUS system’s capability of predicting opening volumes. The cavitation maps co-localized closely with the BBBO location, representing the first report of real-time transcranial 2-D cavitation mapping in the human brain. Larger opening volumes correlated with increased levels of AD biomarkers, including Aβ42/Aβ40 (R2=0.74), Tau (R2=0.95), and P-Tau181 (R2=0.86), assayed in serum-derived EVs sampled 3 days after FUS (N=5). From PET scans, subjects showed a lower Aβ load increase in the treated frontal lobe region compared to the contralateral region. Reduction in asymmetry standardized uptake value ratios (SUVR) correlated with the harmonic cavitation dose (R2>0.9, N=3). Clinical changes in the mini-mental state examination over 6 months were within the expected range of cognitive decline with no additional changes observed as a result of FUS.Conclusion Safety and feasibility of this cost-efficient and portable FUS for BBBO in AD patients were demonstrated with real-time mapping correlating with BBBO volume and a reduction in pathology, as well as serum detection of the AD proteins, Aβ and tau. Our study suggest the potential for accessible FUS treatment in AD, with or without drug delivery.Competing Interest StatementSome of the work presented herein is supported by patents optioned to Delsona Therapeutics, Inc where EEK serves as co-founder and scientific adviser. SB, ANP, R.J., KL, SJG, OY, DK, AKS, AB, and LSH declare no conflict of interest.Clinical TrialNCT04118764Clinical Protocols https://clinicaltrials.gov/study/NCT04118764 Funding StatementNational Institutes of Health grant R01AG038961 (EEK) National Institutes of Health grant R01EB009041 (EEK) Focused Ultrasound Foundation (EEK)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Boards of Columbia University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll study data are included in the main text and/or supplementary materials.AβAmyloid betaADAlzheimer’s diseaseADNIAlzheimer’s disease neuroimaging initiativeAEAdverse eventBBBBlood-brain barrierBBBOBlood-brain barrier openingCCDCumulative cavitation doseCGA-NPICaregiver-administered neuropsychiatric inventoryCTComputed tomographyEVExtracellular vesicleFDAU.S. Food and Drug AdministrationFLAIRFluid-attenuated inversion recoveryFUSFocused ultrasoundGMGray matterGPUGraphics processing unitIRBInstitutional review boardMMSEMini-mental state examinationMRIMagnetic resonance imagingMRMagnetic resonanceMRgFUSMagnetic resonance-guided focused ultrasoundNHPNon-human primateNgFUSNeuronavigation-guided FUSPAMPassive acoustic mappingPCPPassive cavitation detectionPETPositron emission tomographyPRPrecision-recallROCReceiver operating characteristicSAEAdverse eventSUVRStandard uptake value ratioSUVRBBBO*Standard uptake value ratio measured within BBBO volume in the gray and white matterSUVRFLStandard uptake value ratio measured within the treated frontal lobeSUVRHStandard uptake value ratio measured within the treated hemisphereSWISusceptibility-weighted imaging